This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Dyax Corp. Announces Presentation Of KALBITOR® (ecallantide) Pediatric And Abdominal Attack Data At The American College Of Allergy, Asthma And Immunology Annual Meeting (ACAAI)

Dyax Corp. (NASDAQ: DYAX) announced today that two poster presentations featuring updated KALBITOR® (ecallantide) data in pediatric patients with hereditary angioedema (HAE) and HAE patients with abdominal attacks were presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2012 Annual Scientific Meeting, held November 8-13, at the Anaheim Convention Center in Anaheim, CA. Both presentations pooled results from patients enrolled in four different clinical trials of ecallantide for the treatment of acute HAE attacks: DX-88/19, an open-label continuation study; EDEMA2 ®, an open-label, Phase 2 dose-ranging, repeat-dosing study; and EDEMA3 ® and EDEMA4 ®, two Phase 3 double-blind, placebo-controlled studies. KALBITOR is indicated for the treatment of acute attacks of HAE in patients 16 years of age and older.

Commenting on the study “Clinical Trial Experience of Pediatric Patients Treated with Ecallantide for Acute Attacks of Hereditary Angioedema,” Andrew MacGinnitie, MD, PhD, Associate Clinical Director, Division of Immunology at Boston Children’s Hospital, and lead investigator of the study, stated: “In order to provide patients with effective relief from the disease’s often debilitating, acute attacks, it is important that pediatric and other specialist communities learn to diagnose and treat HAE as early as possible.”

“Our clinical studies of KALBITOR reinforce its demonstrated ability to effectively treat various patient populations and attack locations,” commented Dr. Burt Adelman, Executive Vice President and Chief Medical Officer at Dyax Corp. “The presentation of these data is part of our ongoing effort to educate the healthcare community about hereditary angioedema and novel treatments such as KALBITOR. Dyax remains committed to providing an HAE support, education and treatment awareness program that is second to none.”

Complete List of Poster Presentations on KALBITOR at ACAAI 2012

Poster Presentations

  • Clinical Trial Experience of Pediatric Patients Treated with Ecallantide for Acute Attacks of Hereditary Angioedema – Andrew MacGinnitie, MD, PhD, Associate Clinical Director, Division of Immunology, Boston Children’s Hospital, Boston, MA, Poster P303 presented on Saturday, November 10, 12:30-1:30p.m. PST and Sunday, November 11, 12:00-1:00p.m. PST
  • Treatment of Abdominal Attacks of Hereditary Angioedema with Ecallantide – Christopher Stevens, MD, Gastroenterology Medical Consultant, Poster P305 presented on Saturday, November 10, 12:30-1:30p.m. PST and Sunday, November 11, 12:00-1:00p.m. PST

About KALBITOR ® (ecallantide)KALBITOR is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. KALBITOR, which was discovered and developed by Dyax, is the first subcutaneous treatment available in the U.S. for treating acute HAE attacks.

Important KALBITOR Safety InformationAnaphylaxis has been reported after administration of KALBITOR. Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema. Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and patients should be monitored closely. KALBITOR should not be administered to patients with known clinical hypersensitivity to KALBITOR.

As part of product approval, Dyax has implemented a Risk Evaluation and Mitigation Strategy (REMS) program. The goal of the REMS is to communicate the risk of anaphylaxis and the importance of distinguishing between a hypersensitivity reaction and HAE attack symptoms.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs